论文部分内容阅读
为了探讨二丙酸倍氯米松（ＢＤＰ）吸入是否可改善慢性喘息型支气管炎（慢喘支）患者的肺通气功能，随机选取５２例慢喘支患者，加用ＢＤＰ２００～６００μｇ每天气道内吸入，连续使用１个月。治疗前和疗程结束时检查肺通气功能和动脉血气分析。结果：治疗后患者临床症状改善，总有效率（临床控制＋显效）４６２％，治疗前ＦＥＶ１（１秒钟用力呼气量）、ＰＥＦ（最大呼气流量）、ＦＶＣ（最大肺活量）分别为（０８７±０．４４）Ｌ、（２．０７±１．１０）Ｌ／ｓ、（１．５０±０．６５）Ｌ，治疗后分别为（１．０７±０．５３）Ｌ、（２．８６±１．１３）Ｌ／ｓ、（１．６８±０．６５）Ｌ，治疗前Ｐａｃｏ２为（６．０８±１．６９）ｋＰａ，治疗后Ｐａｃｏ２为（５．３７±１．１０）ｋＰａ，Ｐ值均＜００１。口腔真菌感染略增加（Ｐ＞００５），未见全身性副作用。说明低剂量ＢＤＰ气道内雾化吸入可改善慢喘支患者的通气功能。
To investigate whether inhalation of beclomethasone dipropionate (BDP) can improve pulmonary ventilation in patients with chronic asthmatic bronchitis (chronic asthmatic bronchitis), 52 patients with chronic asthma were randomly selected and treated with BDP200 ~ 600μg daily inhalation, Continuous use for 1 month. Check pulmonary ventilation and arterial blood gas analysis before treatment and at the end of the course of treatment. Results: After treatment, the clinical symptoms were improved, the total effective rate (clinical control + effective) was 462%, FEV1 (forced expiratory volume 1 second), PEF (maximum expiratory flow) and FVC Were (0.87 ± 0.44) L, (2.07 ± 1.10) L / s and (1.50 ± 0.65) L, respectively, and were (1.07 ± 0.53) L , (2.86 ± 1.13) L / s and (1.68 ± 0.65) L, respectively. Paco2 was (6.08 ± 1.69) kPa before treatment and Paco2 was (5.37 ± 1 .10) kPa, all P <001. Oral fungal infection slightly increased (P> 0 05), no systemic side effects. Description Low-dose inhaled BDP inhaled airway can improve ventilation in patients with chronic asthma.